Loading…
Employees: 2,298
Size Hunan Jiudian Pharmaceutical (300705.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $789M, the 2800th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥10.52 on 6 Nov 2026.
Performance Over six months the shares fell 18.1%, against -8.0% for the median peer and -16.4% for the China market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue fell 5.3% over the last twelve months (peer median +2.7%); the operating margin is 12.9% (peer median 7.3%).
Valuation It trades at 17.8× forward earnings against a peer median of 16.2× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about -1% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -27 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.2 points above its cost of capital (6.2% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.89B | CN¥3.09B | CN¥2.91B | CN¥2.67B | CN¥2.31B |
| Revenue growth | — | +6% | +9% | +16% | — |
| Gross profit | CN¥1.92B | CN¥2.20B | CN¥2.09B | CN¥2.02B | CN¥1.76B |
| EBITDA | n/a | CN¥669M | CN¥637M | CN¥442M | CN¥338M |
| Net income | CN¥306M | CN¥473M | CN¥512M | CN¥368M | CN¥270M |
| Free cash flow | CN¥137M | -CN¥3.11M | CN¥352M | CN¥6.46M | -CN¥142M |
| Capital expenditure | CN¥537M | CN¥653M | CN¥398M | CN¥427M | CN¥413M |
| Total debt | CN¥799M | CN¥595M | CN¥357M | CN¥430M | CN¥369M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300705.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.6% | -0.4% | 10th lowest of 20 |
| 6-month return | -18.1% | -8.0% | 8th lowest of 20 |
| Distance from 52-week high | -39.4% | -30.4% | 7th lowest of 20 |
| Revenue growth (TTM) | -5.3% | +2.7% | 8th lowest of 19 |
| Operating margin | 12.9% | 7.3% | 6th highest of 19 |
| Forward P/E | 17.8× | 16.2× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | -1.1% | 0.2% | 6th least demanding of 12 |
| Growth delivered (Del g) | +26.1% | +2.1% | highest of 12 |
| Hurdle (Req g minus delivered) | -27.1 pp | -1.4 pp | 2nd least demanding of 12 |
| ROIC minus cost of capital | +6.2 pp | -0.4 pp | 2nd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Hunan Jiudian Pharmaceutical 300705.SZ | China | $789M | -18% | -5% | 13% | 17.8× | -1.1% | +26.1% |
| Collegium Pharmaceutical COLL | United States | $788M | -36% | +14% | 20% | 3.4× | -7.0% | +20.3% |
| Katakura Industries 3001.T | Japan | $791M | +46% | 0% | 16% | n/a | 0.2% | +0.5% |
| Zhuzhou Qianjin Pharmaceutical 600479.SS | China | $787M | -3% | +4% | 11% | n/a | -1.4% | 0.0% |
| Lexicon Pharmaceuticals LXRX | United States | $792M | -11% | -29% | -131% | n/a | n/a | n/a |
| Suven Life Sciences SUVEN.NS | India | $792M | +20% | +17% | -4,228% | n/a | n/a | n/a |
| Bambusa Therapeutics BBTX | United States | $783M | n/a | n/a | n/a | n/a | n/a | n/a |
| Annexon ANNX | United States | $796M | -26% | n/a | n/a | n/a | n/a | n/a |
| Sanofi India SANOFI.NS | India | $800M | -3% | -6% | 26% | 19.9× | 16.5% | -8.7% |
| Knight Therapeutics GUD.TO | Canada | $800M | +37% | +42% | 5% | 76.4× | 9.5% | +17.7% |
| Zhejiang Anglikang Pharmaceutical 002940.SZ | China | $801M | -19% | -6% | 10% | n/a | 18.2% | +2.1% |
| Jiangsu Jibeier Pharmaceutical 688566.SS | China | $777M | -8% | +9% | 24% | 11.9× | 11.5% | +11.3% |
| Youcare Pharmaceutical 688658.SS | China | $776M | -41% | -7% | -13% | 28.8× | n/a | n/a |
| DongKook Pharmaceutical 086450.KS | South Korea | $776M | -1% | +13% | 10% | 12.4× | -6.3% | +10.6% |
| SK Discovery 006120.KS | South Korea | $804M | +11% | +20% | 3% | n/a | n/a | n/a |
| Alumis ALMS | United States | $805M | -27% | -63% | -5,480% | n/a | n/a | n/a |
| Guizhou Xinbang Pharmaceutical 002390.SZ | China | $805M | -10% | -13% | 4% | n/a | -3.0% | -0.8% |
| Chongqing Pharscin Pharmaceutical 002907.SZ | China | $808M | -7% | +8% | 10% | n/a | 10.7% | -1.4% |
| China Traditional Chinese Medicine 0570.HK | Hong Kong | $771M | -29% | -16% | 0% | n/a | n/a | n/a |
| Jinghua Pharmaceutical 002349.SZ | China | $825M | -8% | +2% | 20% | n/a | -1.8% | +2.6% |
| CARsgen Therapeutics 2171.HK | Hong Kong | $825M | -54% | +68% | -170% | n/a | n/a | n/a |